Chardan Capital Cuts CAMP4 Therapeutics (NASDAQ:CAMP) Price Target to $6.00

CAMP4 Therapeutics (NASDAQ:CAMP) had its target price lowered by Chardan Capital from $6.50 to $6.00 in a research report report published on Tuesday morning, Marketbeat reports. The brokerage currently has a buy rating on the Wireless communications provider’s stock.

A number of other analysts also recently weighed in on CAMP. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Piper Sandler restated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Finally, JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CAMP4 Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $10.17.

CAMP4 Therapeutics Stock Down 5.0%

CAMP opened at $3.84 on Tuesday. CAMP4 Therapeutics has a 52 week low of $2.85 and a 52 week high of $7.75. The stock has a market cap of $240.96 million, a PE ratio of -1.66 and a beta of 0.26. The business has a 50 day moving average of $4.14 and a 200-day moving average of $4.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Equities analysts anticipate that CAMP4 Therapeutics will post -0.57 EPS for the current year.

Insider Transactions at CAMP4 Therapeutics

In other news, CFO Kelly Gold purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were bought at an average price of $3.96 per share, for a total transaction of $39,600.00. Following the purchase, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard Young acquired 16,378 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director directly owned 186,388 shares in the company, valued at $307,540.20. The trade was a 9.63% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. 21.69% of the stock is owned by insiders.

Institutional Investors Weigh In On CAMP4 Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC purchased a new position in CAMP4 Therapeutics in the 2nd quarter worth approximately $27,581,000. 5AM Venture Management LLC purchased a new stake in CAMP4 Therapeutics during the 2nd quarter valued at $25,647,928. Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth $8,446,935. BlackRock Inc. bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth $7,185,000. Finally, EcoR1 Capital LLC purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter worth $1,992,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms.

CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes.